Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) - Eli Lilly

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/39230829

Ajay Nirula; Carmen Deveau; Dipak R Patel; Himanshu Upadhyaya; Lisa MacPherson; Mark Williams; Martin Bohm; Matthew M Hufford; Paul Klekotka

Sep 4, 2024